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Abstract
Acromegaly is the condition produced by one of the benign tumors of the pituitary 
gland. These tumors produce a variety of disorders affecting many parts of the body, 
producing side effects related to abnormal hormone function. The dramatic appearance 
of the acromegalic giant has attracted attention over the ages. This chapter summarizes 
the history of the recognition and ultimate diagnosis of acromegaly. The biological and 
physiological elements are described. The methods of diagnosis and management are 
elaborated. Although the focus of the chapter is on the surgical approach for treatment, 
alternative strategies are also discussed, along with the outcomes of management for 
patients and the restoration of quality of life as a primary goal.
Keywords: acromegaly, gigantism, growth hormone, pituitary surgery, endoscopic 
surgery
1. Introduction
By 1800, the existence of human “giants” had been established through legends and stories for 
centuries. Up to that point, the story of “O’Brien the Irish Giant” was one of the most intrigu-
ing. Charles Byrne, O’Brien’s given name, was born in Ireland in 1761 and died in London 
in 1783 at the age of 22 [1]. During the course of his short life, his legend grew to the level of 
national fame in Great Britain and continued after he died. Byrne’s notoriety stemmed from 
his terrific stature, alleged at the time to be 8 feet 4 inches. In truth, he stood at about 7 feet and 
7 inches tall, still towering over the spectators who paid to see him. As a teenager, Byrne left 
Ireland for Britain, where he intended to make a name for himself by displaying his body and 
charging people for the chance to come see him. Sadly, Byrne’s career would end tragically 
one night at a pub where he was robbed of his life’s earnings, as much as £700. He died shortly 
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thereafter. Upon his death, a competition began among medical professionals to secure the 
rights to his corpse, in some cases for the purpose of scientific research, in others out of curios-
ity and greed. Byrne had foreseen this outcome and had made it known that he did not wish 
for anyone to dissect his body after he died, requesting that he be buried at sea [1]. This did 
not stop the pursuit of Byrne’s body, and it was the infamous John Hunter who “managed to 
surreptitiously procure Byrne’s corpse from a dishonest person among Byrne’s companions 
for a large sum, quoted at £500.” [1] Instead of examining Byrne’s pituitary fossa, Hunter was 
actually seeking Byrne’s body as a collector’s item and decided to display the man’s skeleton 
in his museum [2]. For over a century, his skull would remain unexamined; in the meantime, 
the medical world’s understanding of gigantism and acromegaly would grow exponentially.
In 1864, the Italian neurologist Andre Verga first documented a patient who displayed symp-
toms of a certain affliction which he named “prosopectasia,” or a widening of the face, a 
common sign of the disease we now call acromegaly [3] (Figure 1).
That same year, Verga also became one of the earliest investigators to report an acromegalic 
subject with a finding of sellar enlargement, growth of the area of the skull that contains 
the pituitary gland. The major event in the timeline of scientific research was Pierre Marie’s 
creation of the diagnostic term “acromegaly” in 1886 [3]. This marked the first time that the 
characteristics and symptoms of the condition were succinctly summarized and published, 
although works before Marie’s had mentioned many of the same symptoms in patients dis-
playing gigantism [3]. In the years after Marie’s paper, investigators began to understand that 
tumors of the pituitary caused glandular enlargement and were the root of the disease, dis-
pelling previously held notions that they were simply by-products of gigantism. The debate 
still raged about the relationship between acromegaly and gigantism. At first, Marie believed 
acromegaly to be pathological, while gigantism was simply an extreme of normal human 
development. It became apparent after inspecting famous giants’ skeletons that the disorders 
had a “pathogenetic mechanism, but differed with regard to the age of onset.” The consensus 
Figure 1. Verga’s description of prosopectasia (Author’s collection).
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was that gigantism has an earlier onset than acromegaly, appearing while the individual is 
still growing, but that acromegaly occurs after puberty when the person had completed nor-
mal growth [3].
The first decade of the 1900s brought concentrated emphasis on the underlying pathological 
causes behind acromegaly, expanding on the identification of the pituitary as the affected area. 
This research became part of the basis for the entire “hormone theory.” In 1902, E.H. Starling 
and W.M. Bayliss conducted an experiment in which they injected duodenal extract into a 
dog intestine, causing the pancreas to become activated and to secrete what was later termed 
“secretin.” [4] Three years later, with the advice of William Hardy, Starling became the first 
to use the term “hormone” to describe this phenomenon “in which substances produced 
at one site had the ability to bring about physiological changes at a distant site without a 
direct neural stimulus.” [4] At this point, four major theories of the pituitary’s relationship to 
gigantism and acromegaly had emerged. The first, most notably supported by Marie himself, 
was that pituitary hyposecretion was the cause. Rebuking this notion, distinguished mem-
bers of the field, including Massalongo, Tamburini, Benda, Modena, and Fisher, believed that 
acromegaly was due to pituitary hypersecretion [4]. A third theory, supported by Gauthier, 
Strumpell, Vassale, and Guerrini, was that it was merely the result of a nutritional disorder 
and that oversized pituitary fossae were by-products of the disease. Finally, a fourth camp 
maintained that there was no causation whatsoever between the pituitary and acromegaly.
No one was more influential with his or her work on the pituitary than Dr. Harvey Cushing, 
author of The Pituitary Body and Its Disorders, published in 1912 [4]. Cushing was a proponent 
of the second theory that an overactive pituitary led to acromegaly and gigantism. The detail 
in his case studies was second to none, and with his meticulous research, he was able to com-
pile a comprehensive analysis of the disease’s true nature. In fact, Cushing became the first 
person to open the skull of the original Irish Giant, Charles Byrne, in 1909, over a century after 
Byrne’s death. Still held in Hunter’s collection, Byrne’s worst fears became a reality when 
Cushing examined his skull to find that he had, as many had long since assumed, an unnatu-
rally large pituitary fossa. In addition to this momentous discovery, Cushing also described a 
large number of acromegalic patients in his 1912 book (Figure 2).
With the image above, Cushing detailed one of the more striking aspects of the disease, the 
physiological changes to which the affected body is subjected. This instance in particular, 
which was the first to be mentioned in his long list of case studies, shows a man who would 
have been described as simply a “normal giant” before the onset of the disease [5]. By this, 
Cushing meant that while he was an outlier in terms of height before he was afflicted, and 
this was due to natural growth that did not have anything to do with an enlargement of the 
pituitary. It was also at this time that, building upon Starling and Bayliss’s work on hormones, 
Cushing became the first to posit that the pituitary was responsible for secreting a “hormone 
of growth,” a massive step toward what would prove to be the correct understanding of 
gigantism and acromegaly. The way in which modern medicine understands and treats acro-
megaly and gigantism would not have been possible without each person, professional, and 
patient, mentioned in this book, as well as countless others who go unmentioned, who are all 
owed a great deal of gratitude for their contributions.
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2. Making the diagnosis
For most patients, acromegaly is a subtle and slowly progressive illness. The clinical findings 
evolve so slowly that it is often 5–10 years or more before patients seek medical attention. The 
primary symptoms and signs of acromegaly are listed in Table 1. They include progressive 
enlargement of facial features, hands, and feet; enlargement of the jaw with spacing of the 
teeth and malocclusion of bite; increased perspiration, with oily skin and a tendency to have 
acne and skin tags; joint pains; low-back pain; and headache [6].
There are a number of comorbidities characteristic of acromegaly [7]. They include elevated 
blood pressure, diabetes mellitus, obstructive sleep apnea (OSA), snoring, enlargement of the 
tongue and upper airway structures, hyperlipidemia, and, in some cases, cardiomyopathy. 
They are listed in Table 2.
A variety of laboratory testing abnormalities can occur in patients with acromegaly. The cardinal 
features are elevation of serum growth hormone (GH) and IGF-1. Elevations in these hormones 
are present in patients with active acromegaly, and they are essential for making the diagnosis. 
Some patients may have elevations in prolactin as well. Pressure on the normal pituitary gland 
from the tumor can produce a decrease in cortisol, thyroid hormones, and testosterone levels, 
and abnormalities of gonadotropin hormones can produce fertility problems in women.
Because the location of the pituitary tumor that produces acromegaly is at the base of the skull 
in the area called the sella turcica, imaging diagnosis is routinely done by magnetic resonance 
imaging (MRI). Occasionally other imaging studies are helpful in making the diagnosis and in 
planning treatment. These include computerized tomography (CT) scans to accurately evalu-
ate bony structures, angiography to delineate the vascular elements around the area of the 
tumor, and rarely nuclear imaging studies such as PET scans [7, 8]. A typical pituitary tumor 
(macroadenoma) producing acromegaly is seen in Figure 3.
Figure 2. One of Cushing’s acromegaly patients from 1910, “M. Van W.,” the picture on the left shows the subject 
pre-acromegaly at age 25. The middle and right pictures show the same man just 10 years later at 35, with obvious 
acromegalic changes [4].
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3. Classification of growth hormone-secreting tumors in acromegaly
There are two basic characterizations of the size of pituitary tumors. Microadenomas are 
tumors that are less than 10 mm in maximum diameter. Macroadenomas are those tumors 
10 mm or more in maximum diameter. There is also a characterization of uncommon “giant” 
adenomas that are defined as being 3 or 4 cm in maximum diameter. A further classification 
Excessive growth: height, hands, feet, hat size, facial features (brow, nose, lips, tongue, jaw), joints (arthropathies), 
acral bones
Oily skin, acne, excessive sweating (hyperhidrosis), skin tags
Dental gapping, malocclusion
Headache, chest pain
Carpal tunnel syndrome
Table 1. Symptoms and signs of acromegaly.
Hypertension, cardiomyopathy
Diabetes mellitus
Obstructive sleep apnea
Hyperlipidemia
Visual loss (from tumor growth)
Colonic polyps
Table 2. Comorbidities of acromegaly.
Figure 3. MRI images of a large invasive GH macroadenoma.
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is related to tumor cell invasion of the structures around the pituitary. These include invasion 
of the dural membranes surrounding the pituitary and invasion of the cavernous sinuses on 
either side of the pituitary (Knosp grading) [9]. Tumors that extend above the pituitary into the 
suprasellar space can come in contact with the optic chiasm and produce progressive visual 
loss. The size and stage of these tumors help determine both the goals of surgery and the out-
comes for the patients. Occasionally, a pituitary tumor may develop what is called pituitary 
tumor apoplexy [10] wherein there is hemorrhage into the tumor with rapid enlargement, 
sometimes involving an emergency situation requiring prompt surgery and prompt cortisol 
replacement.
4. Indications for surgical management
For the majority of patients, the presence of active acromegaly alone is the indication for 
surgery, in those patients well enough to undergo anesthesia and the surgical procedure. 
In addition to halting the relentless progress of acromegaly, successful surgical removal is 
considered to be “first-line” management [11] and often can also correct visual loss and ame-
liorate intractable and life-threatening comorbidities. Adjunctive and second-line therapies 
include various forms of radiation therapy and a number of pharmacologic approaches that 
are helpful when surgery is either contraindicated or becomes ineffective. Ultimately, the goal 
is improving the quality of life of our patients with acromegaly.
5. Preoperative evaluation and preparation
In patients being considered for general anesthesia and surgery, a careful preoperative evalu-
ation must be performed [12, 13]. This includes obtaining a full panel of pituitary-focused 
laboratory testing, with repletion of any hormones that may be deficient, particularly cortisol 
and thyroid hormone. Repletion of thyroid deficiency must be handled very slowly, as the 
associated increase in metabolic rate may require adding supplementary cortisol to cover 
the stress of surgery. It is also important to note that the serum chemistries are in the normal 
range, especially sodium, potassium, and calcium.
Patients with significant hypertension need to be controlled, and those with a risk of cardio-
myopathy must be fully evaluated by a cardiologist. Those patients with diabetes mellitus 
will need to be managed throughout the surgery and hospitalization to maintain satisfactory 
glucose levels. Patients with symptomatic obstructive sleep apnea may require particular 
attention with regard to airway management during surgery and in the postoperative period. 
It is desirable to alert the anesthesia team in advance for patients who have acromegaly. 
Acromegaly patients often have difficult airways and may require awake fiber-optic intu-
bation. If the imaging studies show that there is a more than the usual risk of damage to 
blood vessels in the region of the pituitary, particularly the carotid arteries, an arterial line 
may be a useful adjunct during anesthesia and postoperatively when and if intensive care 
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unit observation might be necessary. Management of intraoperative fluids and postoperative 
intake and output of fluids is a critical part of the recovery process for the patients, many of 
whom will require a urinary catheter during the operative and the postoperative periods.
In some cases of large, invasive, suprasellar GH-secreting tumors, preoperative medical ther-
apy can be useful in shrinking the size of the tumor, making it smaller and safer to remove 
surgically (Figure 4).
The patient is a 32-year-old aviator. After the onset of loss of libido 8 years prior to surgery, 
he noted the progressive onset of evolving symptoms, including increased shoe and hat size, 
Figure 4. Case illustration. (a) Pre-treatment coronal and sagittal images of invasive GH macroadenoma as seen in 
Figure 3. (b) Post-treatment coronal and sagittal images after 3 months of Lanreotide producing  major shrinkage, 
facilitating the subsequent operation (See Section 9). Postoperatively he had normalization of Growth Hormone and 
IGF-1, and is back flying airplanes!
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jaw enlargement, frontal bossing, skin tags, decreased muscle mass, hyperhidrosis, and loss 
of energy and increasing fatigue. Visual examination revealed 20/20 acuity, bitemporal visual 
field loss, and decreased retinal fiber layer on ocular computerized tomography. Laboratory 
investigation revealed low testosterone, FSH, and LH, slightly elevated prolactin at 21.3, low 
cortisol at 3.6, and elevated growth hormone and IGF-1 at 3.3 and 632, respectively. After 3 
months of treatment with lanreotide (Somatostatin analog), the tumor decreased in size and 
became more amenable to thorough surgical removal.
6. Surgery: methods and considerations
There are two basic routes of access for surgery on patients with acromegaly. Currently, 
the most utilized is a transnasal transsphenoidal approach using either the operating endo-
scope or the operating microscope for visualization [8, 14]. Large tumors that extend into 
the intracranial space and involve the brain, optic chiasm, and major blood vessels are often 
treated with a craniotomy, so that intracranial structures in danger can be fully visualized 
in a safe fashion. Because the access to the pituitary is through the nose and the sphenoid 
sinus, it is often helpful to have the assistance of a qualified otorhinolaryngologist to assist 
with problems such as nasal septal deviations, septal spurs, imperfect pneumatization of the 
sphenoid sinus, and other obstacles that may appear during the approach [15]. Patients with 
acromegaly often have unusually stout bony structures and robust nasal and sinus mucosa 
which can account for significant bleeding if not carefully controlled. Once the sella turcica 
has been opened, the dura of the pituitary is incised, and the pituitary tumor is encountered. 
Every effort is made to spare normal pituitary gland and to accomplish a thorough removal of 
the growth hormone-secreting pituitary adenoma. Occasionally the tumors are invasive of the 
dura and adjacent structures. Removal of these portions can increase the risks of surgery but 
may be essential for developing a complete remission of acromegaly. Some tumors perforate 
the diaphragm of the sella and after their removal can result in an intraoperative spinal fluid 
leak. These leaks must be controlled to avoid meningitis. A practical method is to utilize fat 
taken from the abdomen to fill the empty space left by removing the tumor and secure this 
leak in an effective fashion [8]. The area of leakage through the sella can also be reinforced 
with a carefully constructed nasal septal flap [15]. This strategy for repair has been highly 
effective in preventing postoperative spinal fluid leakage and meningitis. The duration of 
surgery is usually less than 3 hours, and patients awaken promptly after recovering from 
anesthesia.
7. Pathology of pituitary tumors in acromegaly
Tumor specimens from surgery are analyzed with great care. Using immunocytochemical 
techniques, most of the tumors can be fully characterized [16]. The majority express growth 
hormone only. Because the tumors that produce acromegaly and elevated prolactin secretion 
come from the same cell line, a number of them are characterized as growth hormone-prolactin 
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staining where some of the tumor cells will stain for one and/or the other of those two hor-
mones. Another less common variant is the mammosomatotroph tumor where each tumor 
cell can express both growth hormone and prolactin. There is also an acidophil stem cell 
tumor that is a primitive variant of the latter. The hormone staining is related to the granules 
within the tumor cell cytoplasm, and they can be classified as either densely granulated or 
sparsely granulated, with some evidence that the sparsely granulated tumor cells are more 
aggressive. These tumors producing acromegaly, including the plurihormonal variant, are 
derived from a cell lineage expressing the Pit-1 transcription promoter. Additionally, the 
mitotic index is evaluated and the proliferation index of the tumor cells is characterized by 
MIB-1 staining. These studies are very helpful in correlation with the clinical course of the 
patients postoperatively.
8. Potential risks and complications of surgery
In experienced hands, the potential risk of serious complications and adverse events is less 
than 2%. There are, however, potential problems that must be considered and measures taken 
for prevention of complications [8].
There is a risk of infection, including meningitis, and this may be associated with a spinal fluid 
leak that ultimately will need repair. Vascular complications can occur and include injury to 
the carotid arteries, other sources of bleeding from peripheral arteries, veins, and mucous 
membranes. These can result in vasospasm, stroke, and postoperative epistaxis. Problems 
with fluid balance can occur, particularly if the posterior pituitary gland or the infundibulum 
is injured during the operation. This can result in diabetes insipidus which must be carefully 
treated until it resolves or is corrected by medication with DDAVP. Another issue with regard 
to fluid balance is the syndrome of inappropriate secretion of ADH (SIADH) which can result 
in symptomatic hyponatremia which must be carefully and slowly corrected in order to avoid 
serious problems [17].
9. Medical management of acromegaly
Careful studies of the biology and pathology of growth hormone-secreting pituitary tumors 
in acromegaly have led to a number of medical strategies for assisting in the treatment of this 
disorder [5, 11, 13, 18]. The tumor cells that produce increased amounts of growth hormone 
and prolactin are derived from the same cell lineage. For that reason, a dopamine agonist which 
is used to treat hyperprolactinemia is moderately effective in helping to control acromegaly. 
The most commonly used dopamine agonist preparation is cabergoline, usually given by 
mouth twice a week, and it is usually well-tolerated. Another class of medical agents consists 
of somatostatin analogs such as octreotide or lanreotide [5]. They have greater effectiveness 
than cabergoline and also have the possibility of shrinking the size of some growth hormone-
secreting pituitary tumors. They are effective in approximately 60% of patients. Another class 
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of drug to treat acromegaly is pegvisomant [18], a growth hormone receptor antagonist. It is 
given by injection, usually on a daily basis, and is exceedingly expensive at this time. It can 
be used in combination with somatostatin analogs, improving on the individual results of the 
two drugs. None of these medical therapies is completely free of side effects.
10. Adjunctive radiation therapy
Another second-line therapy is the use of radiation, which can be delivered in a variety of dif-
ferent timing schedules and with variations in the radiation physics in a number of different 
modalities that are currently in use [19, 20]. Conventional fractionated teletherapy has been 
used for some time but currently is being supplanted by more focused methodologies termed 
stereotactic radiosurgery. The radiosurgical methods include the Gamma Knife, CyberKnife, 
linear accelerator with multileaf collimator, the proton beam, and the carbon ion beam. Some 
of these can be given by “single shots” or by fractionation. Each of the modalities has its 
advantages and disadvantages. With modern techniques, the risks of damage to surround-
ing neural structures, including the optic nerves and chiasm, and delayed appearance of 
radiation-induced neoplasms are quite low. In patients with acromegaly, there is a fairly long 
delay time for the radiation to gradually lower the growth hormone and IGF-1. Most of the 
techniques currently utilized are effective but are also associated with a significant degree of 
radiation-induced hypopituitarism regarding the other hormones.
11. Criteria for remission after therapy
Clinical signs of remission of acromegaly tend to occur fairly early in those patients who have 
a satisfactory result of treatment. Some clinical signs improve rapidly, especially difficulty 
with the upper airway and snoring, along with the diminishment of excessive perspiration, 
and gradual improvements in the soft tissue issues affecting the hands, feet, and facial fea-
tures. Headache is often alleviated. Arthropathies tend to linger much longer, but ultimately 
improve in many patients. Some patients with hypertension and diabetes will manifest pro-
gressive clinical improvement, which gradually occurs over time. More than 80% of patients 
who have visual compromise are improved postoperatively.
Biochemical remission is critical, and normalization of the serum levels of growth hormone 
and IGF-1 is monitored to assess the pace and degree of remission [11, 14, 15]. It often takes 3 
months or more for IGF-1 to reach its nadir after surgery, but the growth hormone response 
occurs more promptly. Additionally, the dynamics of growth hormone regulation can be 
measured by performing an oral glucose tolerance test and measuring the response of growth 
hormone, which should become significantly decreased after a glucose challenge.
Ordinarily, we wait 3 months to obtain a definitive postoperative MRI scan which will serve 
as a baseline for the future. For the initial few years, annual MRI studies are often recom-
mended, and they are done if there is not a complete remission or if there is a recurrence of 
Growth Disorders and Acromegaly164
symptoms and/or abnormal laboratory results. We recommend that the pituitary hormones 
and IGF-1 be measured every 6 months for the first several years.
12. Outcomes of surgical management of acromegaly
Initial remission of acromegaly as measured by clinical and biochemical criteria occurs in 
50–60% of macroadenomas and 80–90% of microadenomas [11, 13, 21]. Results are less effec-
tive when the surgeon is dealing with large macroadenomas or tumors that are invasive of 
surrounding structures. Postoperative improvement in the management of diabetes mellitus 
and hypertension is seen in approximately 75% of patients. The majority of patients who pres-
ent with obstructive sleep apnea develop improvement after successful surgery. Although 
pituitary adenomas are generally benign tumors that do not progress to malignancy, tumor 
recurrence does develop in some patients over time. After initial successful surgery, recur-
rence will develop in approximately 8% of patients within the first 10 years following success-
ful surgery. Because the objective of all forms of management of acromegaly are to improve 
the quality of life of the patient, a number of questionnaires and instruments have been devel-
oped [21, 22] to measure quality of life, and they provide good insight as to the results of 
current therapy and for areas with needs for improvement. Studies have demonstrated that 
sustained remission of patients with acromegaly provides mortality figures similar to the 
general age-matched population [23]. There is evidence to suggest that significant surgical 
experience is a major factor in achieving optimal outcomes [23]. Although great strides have 
occurred, continuous development of knowledge concerning the genetics and molecular biol-
ogy of acromegaly will undoubtedly provide us with more versatile and effective avenues of 
progress.
13. Conclusion
Acromegaly is the current quintessential example of a hyperfunctioning tumor of the pitu-
itary gland. It is usually a benign tumor; however, it has multiple side effects and comor-
bidities that threaten the life and wellbeing of the patient. Steady progress has been made 
since its original description in understanding the pathophysiology of pituitary adenomas. 
We have learned a great deal about the molecular biology and hypothalamic regulation of 
pituitary cells that secrete growth hormone and induce elevations in IGF-1. At present, the 
first-line therapy is surgery to remove the tumor, usually by the endonasal transsphenoidal 
approach, often with the aid of a surgical endoscope. The results of surgical management 
are generally excellent, and techniques and outcomes are steadily improving. Initial criteria 
for the development of centers of excellence for pituitary adenoma diagnosis and treatment 
are being developed [24]. Surely, further scientific investigation will improve the nonsurgi-
cal adjunctive management of growth hormone-secreting pituitary tumors, primarily using 
appropriate drugs that target the physiological and genetic mechanisms of these tumors that 
secrete excess growth hormone.
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